What is it about?
Review of planning studies to analyze and estimate the risk of radiation induced second cancer.
Featured Image
Why is it important?
For clinically comparable treatment plans, the risk of second cancer should be an important factor in the selection of the treatment. The current study provides the model and organ-dependent excess risk for organs attributable to SABR treatment for lung cancer.
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations. I hope you find this article thought-provoking.
Vasanthan Sakthivel
Read the Original
This page is a summary of: Radiation-induced second cancer risk from stereotactic ablative radiotherapy (SABR) for lung cancer: a review of planning studies, Journal of Radiotherapy in Practice, October 2017, Cambridge University Press,
DOI: 10.1017/s1460396917000528.
You can read the full text:
Contributors
The following have contributed to this page
